Defibrillator News and Research

Latest Defibrillator News and Research

St. Jude Medical's quadripolar pacing system receives European CE Mark approval

St. Jude Medical, Inc. today announced it has received European CE Mark approval for the industry’s first quadripolar pacing system for cardiac resynchronization therapy defibrillators (CRT-Ds). The quadripolar system offers physicians the ability to more effectively and efficiently manage the ever-changing pacing needs of patients with heart failure.

21 Oct 2009

Cardiac Science and OMRON Healthcare sign distribution agreement

Cardiac Science Corporation (Nasdaq: CSCX), a global leader in automated external defibrillator (AED) and diagnostic cardiac monitoring devices, entered into an exclusive agreement with OMRON Healthcare distribute Omron's vital signs and spot check monitors under the Cardiac Science brand in the United States and Canada.

20 Oct 2009

Three deaths in Detroit Marathon highlight the importance of greater public awareness about SDC

The tragic deaths of three runners in Sunday's Detroit Marathon underscore how frequently and indiscriminately sudden cardiac arrest strikes Americans, the Sudden Cardiac Arrest Association said today.

20 Oct 2009

MDEA program is accepting entries for its 2010 competition

The Medical Design Excellence Awards (MDEA) program is accepting entries for its 2010 competition from companies and individuals worldwide involved in the design, engineering, manufacture, or distribution of finished medical devices or packaging products.

15 Oct 2009

Gene variations increase the risk of sudden cardiac death

A multi-national research team has discovered that two genetic factors converge to increase the risk of sudden cardiac death.

14 Oct 2009

SCAA to host Survivor Celebration event to mark SCA Awareness Month

A nationwide gathering of sudden cardiac arrest (SCA) survivors will mark SCA Awareness Month with a Survivor Celebration on Friday, October 9th at 7 p.m. in Chicago. This survivor event, hosted by the Sudden Cardiac Arrest Association (SCAA) at the Hyatt Regency O’Hare, 9300 Bryn Mawr Avenue in Rosemont, is part of three-day program that will make up the organization’s annual meeting.

9 Oct 2009

Boston Scientific begins patient enrollments for MADIT-RIT clinical trial

Boston Scientific Corporation today announced its exclusive sponsorship and first enrollments of the MADIT-RIT clinical trial. This new trial follows in the tradition of three previous landmark trials: MADIT, MADIT II and MADIT-CRT, each exclusively sponsored by Boston Scientific and conducted under the leadership of Principal Investigator Arthur J. Moss, M.D., Professor of Medicine at the University of Rochester.

6 Oct 2009

70% of Americans underestimate the seriousness of SCA

More than 250,000 deaths occur each year as a result of sudden cardiac arrest (SCA). In fact, SCA claims one life every two minutes, taking more lives each year than breast cancer, lung cancer or AIDS. Yet, according to a recent survey issued by the Heart Rhythm Society, more than 70 percent of Americans not only underestimate the seriousness of SCA, but also believe SCA is a type of heart attack.

3 Oct 2009

ZOLL Medical wins U.S. Defense defibrillator contract

ZOLL Medical Corporation, a manufacturer of resuscitation devices and related software solutions, announced today that it has been awarded a follow-on contract for Airworthy CCT defibrillators by the U.S. Defense Logistics Agency. If fully exercised, the potential revenue from the contract could approximate $30 million. The services that can order units against this contract are Army, Navy, Air Force, Marine Corps, and federal civilian agencies.

1 Oct 2009

St. Jude Medical launches new cardiac rhythm management devices

St. Jude Medical, Inc. today announced it has launched several new cardiac rhythm management devices for the treatment and diagnosis of abnormal heart rhythms.

30 Sep 2009

Spectranetics seeks FDA clearance for treating in-stent restenosis in the legs

Spectranetics Corporation today announced that it has filed a 510(k) application with the Food and Drug Administration seeking clearance for the treatment of in-stent restenosis (ISR) in the legs with its commercially available peripheral atherectomy products. ISR is caused by the re-growth of tissue within the stent, known as neointimal hyperplasia, which can lead to blockages in the affected leg artery.

29 Sep 2009

Continuous chest compressions during CPR improve survival rates during cardiac arrest

Maximizing the proportion of time spent performing chest compressions during cardiopulmonary resuscitation (CPR) substantially improves survival in patients who suffer cardiac arrest outside a hospital setting, according to a multicenter clinical study that included UT Southwestern Medical Center.

29 Sep 2009

Oxygen Biotherapeutics submits a patent application for its heart attack treatment device

Oxygen Biotherapeutics, Inc. today announced that the company has submitted a patent application for a new invention that uses Oxycyte(R) perfluorocarbon to deliver oxygen as a first aid treatment for victims of heart attacks and strokes. Oxycyte is the Company's perfluorocarbon (PFC) therapeutic oxygen carrier.

24 Sep 2009

First Analyses of TYRX's AIGISRx Anti-Bacterial Envelope Retrospective Registry

TYRX, Inc., a leader in the commercialization of implantable medical-pharmaceutical devices, will present the first analyses of results from its AIGISRx Anti-Bacterial Envelope Retrospective Registry during the Transcatheter Cardiovascular Therapeutics (TCT 2009) meeting in San Francisco, CA.

21 Sep 2009

Sudden Cardiac Arrest Foundation launches second video awareness contest on YouTube

To celebrate National Sudden Cardiac Arrest Awareness Month in October, the Sudden Cardiac Arrest Foundation today announced the launch of its second 'You Can Save a Life(TM)' video awareness contest on YouTube.

16 Sep 2009

Implantable defibrillator therapy not beneficial for women with heart failure

Implantable cardioverter-defibrillators do not appear to be associated with a reduced risk of death in women with advanced heart failure, according to a meta-analysis of previously published research in the September 14 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

15 Sep 2009

IMPROVE HF clinical trial results presented at annual HFSA meeting

Twenty-four month findings from IMPROVE HF, (The Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting), funded by Medtronic, Inc., demonstrated that clinics using the process improvement program increased adherence to evidence-based, guideline-recommended care by 82 and 62 percent, respectively, for cardiac resynchronization therapy (CRT) and implantable cardioverter-defibrillator (ICD) use, and 80 percent for aldosterone antagonist use, all relative to baseline results.

15 Sep 2009

OptiVol for accurate prediction of heart failure

Fluid monitoring with OptiVol® Fluid Status Monitoring is a more accurate predictor of worsening heart failure compared to daily weight monitoring in heart failure patients with implantable devices, according to results released today from the FAST (Fluid Accumulation Status Trial) clinical trial.

15 Sep 2009

HFSA's annual scientific meeting features four late breaking clinical trials

The 13th Annual Scientific Meeting of the Heart Failure Society of America (HFSA) today featured four late breaking clinical trials at the Hynes Convention Center in Boston.

15 Sep 2009

TYRX to exhibit AIGISRx Anti-Bacterial Envelope at HFSA

TYRX, Inc., a leader in the commercialization of implantable medical-pharmaceutical devices, announced today that it will be exhibiting its lead product, AIGISRx Anti-Bacterial Envelope, at the 13th Annual Heart Failure Society of America Meeting (HFSA), in Boston, MA this week.

14 Sep 2009